Frequently Asked Questions

The UroLift System treatment is a proven, minimally invasive approach for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) that can get men off BPH medications and avoid major surgery.¹ During a minimally invasive, outpatient procedure, the UroLift System’s permanent implants immediately relieve prostate obstructions and open the urethra directly without cutting, heating, ablating, or removing tissue.²

• The UroLift Delivery Device is placed through the urethra to access the enlarged prostate.
• Small implants are permanently placed to lift and hold the enlarged prostate tissue out of the way and increase the opening of the urethra.
• The UroLift System procedure provides symptom relief by opening the obstructed urethra to improve flow and provide lasting BPH symptom relief.³

There is no cutting, heating, ablating, or removing tissue; this makes the Urolift System one of the few Benign Prostatic Hyperplasia (BPH) treatments that do not remove prostate tissue.²

The UroLift System does not keep someone from having future BPH treatments if they are necessary.

 The UroLift Implants are small permanent implants that hold the obstructing prostatic lobes apart. They are deployed through a needle that comes out of the delivery device. Each implant is made with common implantable materials: nitinol*, stainless steel, and PET suture. The number of implants used in a procedure is determined by the treating physician and will vary by patient. 

 See Procedures and Device for More Information 

References: 

*Warning: This device contains stainless steel and nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, discuss any allergy/hypersensitivity to these materials with your physician.

1. Stanford Biodesign Case Study: Biodesign in BPH, 2015    2. Roehrborn, Can J Urol 2017    3. Gratzke, BJU Int 2017

 MAC03242-02 Rev A

Over 500,000 Urolift System treatments have been performed worldwide.¹ An estimated 2.5 million implants have been delivered to patients.¹ 

 A physician who specializes in the treatment of diseases of the urinary system and reproductive organs, uses the UroLift System to treat urinary symptoms due to BPH. Comprehensive training is provided to the physician prior to using the UroLift System.

 Find a UroLift System Doctor 

The UroLift procedure can be performed in your physician’s office, ambulatory surgical center (ASC), or hospital setting as an outpatient procedure.² Most men go home typically 1-2 hours after the procedure.

References:

1. Management estimate based on product sales as of June 2024. Data on file Teleflex Interventional Urology    2. Shore, Can J Urol 2014

     MAC03242-03 Rev A

You may be a candidate if you are a male, 45 years of age or older, have symptoms relating to BPH, and your prostate size is 100 grams or smaller. Speak with your urologist to see if the UroLift™ System treatment is right for you.  

 Find a UroLift System Trained Physician 

Your physician will determine which examinations are appropriate for you. The physician will likely ask you to fill out a questionnaire to assess your symptoms, called IPSS (International Prostate Symptom Score). Additionally, some of the common examinations include a cystoscopy, Digital Rectal Exam (DRE), Transrectal Ultrasonography (TRUS), bladder ultrasound, and urinalysis. 

 Find your IPSS Symptom Score 

  MAC03242-04 Rev A

The UroLift System treatment may be performed with local or under general anesthesia.¹  Your doctor may give you medication to make you feel more comfortable during the procedure, though everyone's tolerance for pain and discomfort varies greatly. The UroLift System procedure typically takes less than an hour. Most men go home typically 1-2 hours after the procedure. 

Most common side effects are temporary and can include discomfort when urinating, urgency, inability to control the urge, pelvic pain, and some blood in the urine.² Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Speak with your doctor to determine if you may be a candidate for the UroLift System treatment.

See the UroLift System Instructions for Use for more information.

As with any medical procedure, the UroLift System procedure comes with risks. Most common side effects are mild to moderate and temporary and can include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate and/or the inability to control the urge.² Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention.

See the UroLift System Instructions for Use for more information.

References:

1. Shore, Can J Urol 2014    2. Roehrborn, J Urology 2013

  MAC03242-05 Rev A

There is minimal downtime post-treatment and many patients experience symptom relief in as early as 2 weeks.^1,2 The most common side effects may include blood in the urine, some pain or discomfort when urinating, some increased urge to go and discomfort in the pelvis that typically resolve within two to four weeks after the procedure.² Medications are not typically required after recovering from the UroLift treatment.³ Your doctor may prescribe short-term medications such as pain relievers or antibiotics depending on your individual needs. However, about 9 out of 10 patients treated with UroLift did not require BPH medications at 5 years.²

Typically, no catheter is required after treatment, but some men may require a catheter after the procedure to help drain the bladder and assist in the healing process.^1,2 Please discuss this with your urologist prior to your UroLift procedure.

In our clinical studies, the most common side effects are temporary and can include discomfort when urinating, urgency, inability to control the urge, pelvic pain, and some blood in the urine.² Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention.

See the UroLift System Instructions for Use for more information.

Our pivotal study has shown the UroLift System treatment did not cause new, sustained instances of erectile or ejaculatory dysfunction.*³ The only leading BPH procedure** shown to not cause sexual dysfunction.*^4,5

References:

*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study

**Procedures with greater than 5% market share. Data on file.

1. Shore, Can J Urol 2014    2. Roehrborn, J Urology 2013    3. Roehrborn, Can J Urol 2017    4. AUA BPH Guidelines 2003, 2020    5. McVary, Urology 2019

  MAC03242-06 Rev A

Non-clinical testing has demonstrated that the UroLift Implant is MR Conditional.

Which means that patients with UroLift Implants can undergo an MRI scan safely provided specific MRI conditions are met. Upon UroLift implantation, patients receive a Patient Implant Card which outlines technical conditions required for a safe scan. The label does not need to be affixed to be active.

For further information on the specifications, please access the printable digital version of our patient implant card. If you have any questions about MRI safety, please consult your doctor. Always inform your doctor and the MRI technician that you have UroLift implants before your scan.

The implants are not expected to interfere with a DRE. The implants are placed on the anterior (front) side of the prostate, and a DRE is conducted on the posterior (back) side of the prostate.

  MAC03242-07 Rev A

Our pivotal study with the Urolift System treatment has reported durable outcomes out to 5 years.¹ 

A real-world study found that 88.4% of UroLift patients did not require a secondary surgical procedure through 5-years².

See Publications for more information

The UroLift System implant is designed to be a permanent implant. The UroLift implants are made from standard surgical materials and have been tested for biocompatibility.

A real-world study showed that 88.4% of patients receiving the UroLift System treatment did not need a second surgical treatment through 5-years.²

The UroLift System treatment does not prevent future UroLift System, TURP, or laser procedures if recommended by your physician.¹

The UroLift™ System is the only leading BPH MIST* with consistent durability in a controlled trial and real-world setting.^1,2,3 The UroLift™ System is a comprehensively studied minimally invasive BPH procedure, with over 145 peer-reviewed and 22 sponsored publications.

The UroLift procedure is a minimally invasive procedure which can be performed as a same day outpatient procedure, including the office setting, under local anesthesia.⁴ The UroLift™ system treatment is a minimally invasive procedure, it has rapid symptom relief and recovery.^4,5

^References: 

^{*Rezūm™, UroLift™ System}

^{1. Roehrborn, Can J Urol 2017    2. Kaplan, Prostate Cancer Prostatic Dis 2023    3. U.S. 2023 estimates based on US Market Model 2023-25 (3-14-23 FINAL), which is in part based on Symphony Health PatientSource® 2018-22, as is and with no representations/warranties, including accuracy or completeness.    4. Shore, Can J Urol 2014    5. Roehrborn, J Urology 2013}

See Treatment Options for more information

  MAC03242-08 Rev A

Most carriers cover UroLift including Medicare, Anthem, BC/BS, UHC, Aetna and TriCare. Contact your insurance company for more information.

   MAC03242-09 Rev A